Anti-depressant approved for severe PMS
The Food and Drug Administration (FDA) recently approved the prescription anti-depressant drug Zoloft for the treatment of premenstrual dysphoric disorder (PMDD).
PMDD is a more serious form of premenstrual syndrome (PMS) which affects about 3-5 percent of menstruating women. The symptoms are similar to PMSincluding mood swings, irritability, tension, fatigue, change in appetite, sleep difficulties and bloatingbut are severe enough to interfere with everyday life.
Zoloft is now the second anti-depressant to be approved for treatment of PMDD. The first drug approved for this indication was Sarafem, which is an alternate brand name for the drug otherwise sold as Prozac (fluoexetine).